Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is dedicated to providing expert cancer care, groundbreaking treatments, and innovative research for adult and pediatric patients. Since 1947, it has focused on research, diagnosis, treatment, and prevention of cancer, with a mission to eradicate cancer and related diseases. The institute collaborates with various hospitals and research institutions, offers clinical trials, and has specialized centers for different cancer types, including rare diseases like histiocytosis and childhood tumors. It emphasizes community health, diversity, and innovation in cancer research and treatment, and is recognized globally for its leadership in oncology.
Industries
Nr. of Employees
Very Large (1000+)
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, North America
Patents
Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
US-12337034-B2
View DetailsDegradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
US-12329821-B2
View Details
Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
US-12337034-B2
View DetailsDegradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
US-12329821-B2
View DetailsProducts
International pediatric LCH treatment protocol (LCH‑IV)
A multicenter, prospective protocol for children and adolescents with Langerhans cell histiocytosis that defines strata for initial therapy, progressive disease and severe organ dysfunction and includes long-term follow-up.
Personalized neoantigen vaccine protocol for newly diagnosed glioblastoma (Phase I)
Phase I study evaluating safety and feasibility of individualized tumor‑mutation‑directed peptide vaccines administered with radiotherapy and cohorts combining immune checkpoint therapy and standard chemotherapy for specific molecular subgroups.
Personalized neoantigen vaccine pilot protocol in IGHV‑unmutated CLL
Pilot feasibility study of individualized neoantigen peptide vaccines with or without low‑dose immunomodulatory agents in asymptomatic, treatment‑naïve IGHV‑unmutated chronic lymphocytic leukemia.
Phase I dose‑escalation trial of a HIF‑2α inhibitor in advanced clear cell RCC
Early‑phase multiple‑dose dose‑escalation trial to determine maximum tolerated dose / recommended Phase II dose of a targeted small molecule inhibitor, including combination cohorts with immune checkpoint inhibitors or targeted agents.
International pediatric LCH treatment protocol (LCH‑IV)
A multicenter, prospective protocol for children and adolescents with Langerhans cell histiocytosis that defines strata for initial therapy, progressive disease and severe organ dysfunction and includes long-term follow-up.
Personalized neoantigen vaccine protocol for newly diagnosed glioblastoma (Phase I)
Phase I study evaluating safety and feasibility of individualized tumor‑mutation‑directed peptide vaccines administered with radiotherapy and cohorts combining immune checkpoint therapy and standard chemotherapy for specific molecular subgroups.
Personalized neoantigen vaccine pilot protocol in IGHV‑unmutated CLL
Pilot feasibility study of individualized neoantigen peptide vaccines with or without low‑dose immunomodulatory agents in asymptomatic, treatment‑naïve IGHV‑unmutated chronic lymphocytic leukemia.
Phase I dose‑escalation trial of a HIF‑2α inhibitor in advanced clear cell RCC
Early‑phase multiple‑dose dose‑escalation trial to determine maximum tolerated dose / recommended Phase II dose of a targeted small molecule inhibitor, including combination cohorts with immune checkpoint inhibitors or targeted agents.
Services
Specialized centers delivering coordinated care for specific diseases with multidisciplinary teams and subspecialty referrals.
Identification, enrollment and onsite management of patients for investigator‑initiated and consortium clinical trials across disease areas and phases.
Clinical genetic assessment and testing services to evaluate hereditary risk and to inform disease classification and trial eligibility.
Long-term clinics addressing physical, cognitive and psychosocial late effects of childhood cancer, including return-to-school and rehabilitation services.
Diagnostic imaging (MRI/CT) and neurosurgical procedures to relieve hydrocephalus and perform tumor resections with perioperative care.
Onsite conduct of early‑phase trials testing individualized tumor‑mutation‑directed peptide vaccines combined with radiotherapy, checkpoint inhibitors and/or adjuvants.
Specialized centers delivering coordinated care for specific diseases with multidisciplinary teams and subspecialty referrals.
Identification, enrollment and onsite management of patients for investigator‑initiated and consortium clinical trials across disease areas and phases.
Clinical genetic assessment and testing services to evaluate hereditary risk and to inform disease classification and trial eligibility.
Long-term clinics addressing physical, cognitive and psychosocial late effects of childhood cancer, including return-to-school and rehabilitation services.
Diagnostic imaging (MRI/CT) and neurosurgical procedures to relieve hydrocephalus and perform tumor resections with perioperative care.
Onsite conduct of early‑phase trials testing individualized tumor‑mutation‑directed peptide vaccines combined with radiotherapy, checkpoint inhibitors and/or adjuvants.
Expertise Areas
- Clinical trial management and operations
- Pediatric neuro‑oncology
- Hematologic malignancies and histiocytic disorders
- Translational drug discovery and experimental therapeutics
Key Technologies
- Phase I–III clinical trial methodologies (dose‑escalation, expansion cohorts)
- Pharmacokinetics and pharmacodynamics (PK/PD) assessments
- Personalized neoantigen vaccine design and manufacturing
- Whole‑exome and transcriptome sequencing (WES/RNA‑seq)
News & Updates
Ceremony marking the start of construction for the Dana-Farber Cancer Center, a major milestone in the institute's history.
The groundbreaking ceremony for the Jimmy Fund Building, which became a state-of-the-art home for laboratories, offices, and the Jimmy Fund Clinic.
A detailed biography of Sidney Farber, the founder of Dana-Farber, highlighting his groundbreaking work in childhood leukemia and his vision for cancer research.
Sidney Farber achieved the first reported clinical remission of childhood leukemia using chemotherapy, a milestone in cancer treatment.
Fundraising and community efforts led to the creation of the Jimmy Fund and the establishment of Dana-Farber as a leading cancer research and treatment center.
Ceremony marking the start of construction for the Dana-Farber Cancer Center, a major milestone in the institute's history.
The groundbreaking ceremony for the Jimmy Fund Building, which became a state-of-the-art home for laboratories, offices, and the Jimmy Fund Clinic.
A detailed biography of Sidney Farber, the founder of Dana-Farber, highlighting his groundbreaking work in childhood leukemia and his vision for cancer research.
Sidney Farber achieved the first reported clinical remission of childhood leukemia using chemotherapy, a milestone in cancer treatment.
Fundraising and community efforts led to the creation of the Jimmy Fund and the establishment of Dana-Farber as a leading cancer research and treatment center.